Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05292040 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3857210 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05292040 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 10 participants.
The verdict
NCT05292040, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \[18F\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.
Interventions
- DRUG LY3857210
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05292040
The ClinicalTrials.gov registry entry for NCT05292040 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY3857210 is the first listed.
NCT05292040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05292040 about?
NCT05292040 is a clinical study titled "A Study of LY3857210 in Healthy Participants". The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \[18F\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to ap...
What is the current status of trial NCT05292040?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-03-17. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT05292040?
The interventions under investigation include: LY3857210 (DRUG).
Who is sponsoring clinical trial NCT05292040?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.